Protopic

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

takrolimus

Available from:

LEO Pharma A/S

ATC code:

D11AH01

INN (International Name):

tacrolimus

Therapeutic group:

Drugi dermatološki preparati

Therapeutic area:

Dermatitis, Atopic

Therapeutic indications:

Flare treatmentAdults and adolescents (16 years of age and above)Treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. Children (two years of age and above)Treatment of moderate to severe atopic dermatitis in children (two years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids. Maintenance treatmentMaintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i. nastale štiri ali večkrat na leto), ki so imeli začetni odziv na največ šest tednov, zdravljenje dvakrat na dan tacrolimus mazilo (lezije, izbrisani, skoraj izbrisani, ali lahko vpliva).

Product summary:

Revision: 26

Authorization status:

Pooblaščeni

Authorization date:

2002-02-27

Patient Information leaflet

                                32
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
LEO Pharma A/S
Industriparken 55
2750 Ballerup
Danska
12.
ŠTEVILKE DOVOLJENJ ZA PROMET
EU/1/02/201/005 10 g
EU/1/02/201/001 30 g
EU/1/02/201/002 60 g
13.
ŠTEVILKA SERIJE
Lot
14.
NAČIN IZDAJANJA ZDRAVILA
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Protopic 0,03%
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA_ _
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI_ _
PC:
SN:
NN:
33
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH
OVOJNINAH
PROTOPIC 0,03% MAZILO (10 G TUBA)
1.
IME ZDRAVILA IN POT UPORABE
Protopic 0,03% mazilo
takrolimus monohidrat
dermalna uporaba
2.
POSTOPEK UPORABE
Pred uporabo preberite priloženo navodilo!
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
4.
ŠTEVILKA SERIJE
Lot
5.
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT
10 g
6.
DRUGI PODATKI
Zdravilo shranjujte nedosegljivo otrokom!
Shranjujte pri temperaturi do 25 °C.
EU/1/02/201/005
34
PODATKI NA PRIMARNI OVOJNINI
PROTOPIC 0,03% MAZILO (30 G, 60
G TUBA)
1.
IME ZDRAVILA
Protopic 0,03% mazilo
takrolimus monohidrat
2.
NAVEDBA ENE ALI VEČ UČINKOVIN
1 g mazila vsebuje 0,3 mg takrolimusa (v obliki monohidrata).
3.
SEZNAM POMOŽNIH SNOVI
beli vazelin, tekoči parafin, propilenkarbonat, beli vosek, trdi
parafin, butilhidroksitoluen (E321),
_vseracemni_
-α-tokoferol.
4.
FARMACEVTSKA OBLIKA IN VSEBINA
Mazilo
30 g
60 g
5.
POSTOPEK IN POT UPORABE ZDRAVILA
dermalna uporaba
Pred uporabo preberite priloženo navodilo!
6.
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN
POGLEDA OTROK
Zdravilo shranjujte nedosegljivo otrokom!
7.
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA
8.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
Shranjujte pri temperaturi do 25 °C.
35
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ 
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Protopic 0,03% mazilo
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
1 g zdravila Protopic 0,03% mazilo vsebuje 0,3 mg takrolimusa v obliki
takrolimus monohidrata
(0,03%).
Pomožna snov z znanim učinkom:
Butilhidroksitoluen (E321) 15 mikrogramov/g mazila.
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
mazilo
Belo do rahlo rumenkasto mazilo.
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Zdravilo Protopic 0,03% mazilo je indicirano pri odraslih,
mladostnikih in otrocih, starih 2 leti in več.
Zdravljenje izbruha bolezni
_Odrasli in mladostniki (stari 16 let in več)_
Zdravljenje zmernega do hudega atopičnega dermatitisa pri odraslih,
ki se na konvencionalne terapije,
kot so lokalni kortikosteroidi, ne odzovejo ustrezno ali jih ne
prenesejo.
_Otroci (stari 2 leti in več)_
Zdravljenje zmernega do hudega atopičnega dermatitisa pri otrocih, ki
se na konvencionalne terapije,
kot so lokalni kortikosteroidi, ne odzovejo ustrezno.
Vzdrževalno zdravljenje
Zdravljenje zmernega do hudega atopičnega dermatitisa za
preprečevanje ponovnega izbruha bolezni
in podaljševanje obdobij brez izbruha bolezni pri bolnikih z zelo
pogostim (to je 4- ali večkrat letnim)
poslabšanjem in začetnim odzivom na največ 6-tedensko zdravljenje z
mazilom s takrolimusom
dvakrat na dan (spremembe so izginile, so skoraj izginile ali je koža
ostala le rahlo prizadeta).
4.2
ODMERJANJE IN NAČIN UPORABE
Zdravljenje z zdravilom Protopic morajo uvesti zdravniki, ki imajo
izkušnje z diagnosticiranjem in
zdravljenjem atopičnega dermatitisa.
Zdravilo Protopic je na voljo v dveh jakostih: kot Protopic 0,03% in
Protopic 0,1% mazilo.
3
Odmerjanje
Zdravljenje izbruha bolezni
Zdravilo Protopic se lahko uporablja za kratkotrajno in dolgotrajno
zdravljenje s prekinitvami.
Dolgotrajno zdravljenje ne sme biti neprekinjeno.
Zdravljenje z zdravilom Protopic je treba začeti ob prvem pojavu
znakov in simptomov. Vsak
prizadeti predel kože je treba zdraviti z zdravilom
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 13-02-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 13-02-2024
Public Assessment Report Public Assessment Report Bulgarian 16-08-2011
Patient Information leaflet Patient Information leaflet Spanish 13-02-2024
Public Assessment Report Public Assessment Report Spanish 16-08-2011
Patient Information leaflet Patient Information leaflet Czech 13-02-2024
Public Assessment Report Public Assessment Report Czech 16-08-2011
Patient Information leaflet Patient Information leaflet Danish 13-02-2024
Public Assessment Report Public Assessment Report Danish 16-08-2011
Patient Information leaflet Patient Information leaflet German 13-02-2024
Public Assessment Report Public Assessment Report German 16-08-2011
Patient Information leaflet Patient Information leaflet Estonian 13-02-2024
Public Assessment Report Public Assessment Report Estonian 16-08-2011
Patient Information leaflet Patient Information leaflet Greek 13-02-2024
Public Assessment Report Public Assessment Report Greek 16-08-2011
Patient Information leaflet Patient Information leaflet English 13-02-2024
Public Assessment Report Public Assessment Report English 16-08-2011
Patient Information leaflet Patient Information leaflet French 13-02-2024
Public Assessment Report Public Assessment Report French 16-08-2011
Patient Information leaflet Patient Information leaflet Italian 13-02-2024
Public Assessment Report Public Assessment Report Italian 16-08-2011
Patient Information leaflet Patient Information leaflet Latvian 13-02-2024
Public Assessment Report Public Assessment Report Latvian 16-08-2011
Patient Information leaflet Patient Information leaflet Lithuanian 13-02-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 13-02-2024
Public Assessment Report Public Assessment Report Lithuanian 16-08-2011
Patient Information leaflet Patient Information leaflet Hungarian 13-02-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 13-02-2024
Public Assessment Report Public Assessment Report Hungarian 16-08-2011
Patient Information leaflet Patient Information leaflet Maltese 13-02-2024
Public Assessment Report Public Assessment Report Maltese 16-08-2011
Patient Information leaflet Patient Information leaflet Dutch 13-02-2024
Public Assessment Report Public Assessment Report Dutch 16-08-2011
Patient Information leaflet Patient Information leaflet Polish 13-02-2024
Public Assessment Report Public Assessment Report Polish 16-08-2011
Patient Information leaflet Patient Information leaflet Portuguese 13-02-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 13-02-2024
Public Assessment Report Public Assessment Report Portuguese 16-08-2011
Patient Information leaflet Patient Information leaflet Romanian 13-02-2024
Public Assessment Report Public Assessment Report Romanian 16-08-2011
Patient Information leaflet Patient Information leaflet Slovak 13-02-2024
Public Assessment Report Public Assessment Report Slovak 16-08-2011
Patient Information leaflet Patient Information leaflet Finnish 13-02-2024
Public Assessment Report Public Assessment Report Finnish 16-08-2011
Patient Information leaflet Patient Information leaflet Swedish 13-02-2024
Public Assessment Report Public Assessment Report Swedish 16-08-2011
Patient Information leaflet Patient Information leaflet Norwegian 13-02-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 13-02-2024
Patient Information leaflet Patient Information leaflet Icelandic 13-02-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 13-02-2024
Patient Information leaflet Patient Information leaflet Croatian 13-02-2024

Search alerts related to this product

View documents history